Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
- Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo
- Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA®
- Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors
Barcelona, Spain, 14 October 2025: Ona Therapeutics (“Ona”), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced the appointment of Dr. Antoine Yver, M.D., M.Sc., as Chair of its Board of Directors. This strategic appointment marks a defining step in the Company’s growth as it prepares to advance its lead ADC, ONA-255, into clinical trials for breast cancer treatment in early 2026.
